ABSTRACT

Background: In India, about 6% of people take statins, which are drugs that block the enzyme 3- hydroxy- 3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Statins reduce the number of low-density lipoproteins (LDL) in the blood, which lowers the risk of cardiovascular events. Muscle aches and pains are a clinically significant adverse effect of statin therapy. Aim: The aim of the study is to assess the incidence of myopathy in drug induced (statin) conditions by evaluating the serum creatine phosphokinase. To investigate the incidence of statin-induced myopathy and its risk factors. Methodology: A six-month prospective observational study is suggested at the Government General Hospital in Guntur. To determine the relationship between them, a logistic regression analysis was used. Results: Of the 114 subjects, 8 (7.02%) had confirmed myopathy with elevation of Sr. CPK. The mean onset of myopathy was observed from 6weeks. In our study, however, statin-associated myopathy affected 7.02% of individuals taking statins. Conclusion: Statin medication should be stopped and serum CK levels should be evaluated if myopathy is suspected. Early detection and treatment of symptomatic CK increases, as well as the discontinuation of pharmacological therapy that may be linked to myopathy, can help prevent rhabdomyolysis. Keywords: Statins, Serum cholesterol, Serum creatine phosphokinase, HMG-Co A reductase, Myopathy, Rhabdomyolysis, Myalgia
Publication date: 01/05/2026

https://www.ijbpas.com/pdf/2026/May/MS_IJBPAS_2026_10119.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.5.10119